Efficacy of fish oil on serum of TNF α, IL-1 β, and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Ramirez Ramirez, V ^a   Macias Islas, M A ^a   Ortiz, G G ^a   Pacheco Moises, F ^b   Torres Sanchez, E D ^a   Sorto Gomez, T E ^a   Cruz Ramos, J A ^a   Orozco Avina G ^c   Celis De La Rosa, A J ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c Instituto de Investigación de la Inflamación   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEMS; CHRONIC INFLAMMATORY DISEASE; DOCOSAHEXAENOIC ACID; NEUROPROTECTIVE EFFECTS; OMEGA-3 POLYUNSATURATED FATTY ACIDS; OXIDATIVE STRESS MARKERS; PROINFLAMMATORY CYTOKINES; SIGNIFICANT DIFFERENCES;

NITRIC OXIDE; OXIDATIVE STRESS; POLYUNSATURATED FATTY ACIDS; TISSUE;

BODY FLUIDS;

CYTOKINE; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; INTERFERON BETA SERINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID PEROXIDE; NITRIC OXIDE; OMEGA 3 FATTY ACID; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; BETA INTERFERON;

ADULT; ANNUALIZED RELAPSES RATE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROPROTECTION; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; BLOOD; DRUG EFFECTS; CONTROLLED CLINICAL TRIAL; DRUG EFFECT;

ADULT; ANIMALS; FEMALE; HUMANS; INTERFERON-BETA; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880179627     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/709493     Document Type: Article

References (45)

1. Nakahara J., Maeda M., Aiso S., Suzuki N., Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clinical Reviews in Allergy and Immunology 2012 42 1 26 34 2-s2.0-84857052288 10.1007/s12016-011-8287-6
2. Riccio P., The molecular basis of nutritional intervention in multiple sclerosis: a narrative review. Complementary Therapies in Medicine 2011 19 4 228 237 2-s2.0-79961170674 10.1016/j.ctim.2011.06.006
3. Bazan N. G., Musto A. E. M., Knott E. J. K., Endogenous signaling by omega-3 docosahexaenoic acid-derived mediators sustains homeostatic synaptic and circuitry integrity. Molecular Neurobiology 2011 44 3 216 222 2-s2.0-80054857565 10.1007/s12035-011-8200-6
4. Selmi C., Tsuneyama K., Nutrition, geoepidemiology, and autoimmunity. Autoimmunity Reviews 2010 9 5 A267 A270 2-s2.0-77649238845 10.1016/j.autrev. 2009.12.001
5. Gallai V., Sarchielli P., Trequattrini A., Franceschini M., Floridi A., Firenze C., Alberti A., Di Benedetto D., Stragliotto E., Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. Journal of Neuroimmunology 1995 56 2 143 153 2-s2.0-0028837184 10.1016/0165-5728(94) 00140-J
6. Torkildsen O., Wergeland S., Bakke S., Beiske A. G., Bjerve K. S., Hovdal H., Midgard R., Lilleas F., Pedersen T., Bjornara B., Dalene F., Kleveland G., Schepel J., Olsen I. C., Myhr K. M., omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Archives of Neurology 2012 69 1044 1051
7. Mehta L. R., Dworkin R. H., Schwid S. R., Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nature Clinical Practice Neurology 2009 5 2 82 92 2-s2.0-59849113527 10.1038/ncpneuro1009
8. Farooqui A. A., Horrocks L. A., Farooqui T., Modulation of inflammation in brain: a matter of fat. Journal of Neurochemistry 2007 101 3 577 599 2-s2.0-34247330919 10.1111/j.1471-4159.2006.04371.x
9. Calder P. C., n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. American Journal of Clinical Nutrition 2006 83 6 1505S 1519S 2-s2.0-33746830525
10. Ortiz G. G., Macías-Islas M. Á., Pacheco-Moisés F. P., Cruz-Ramos J. A., Sustersik S., Barba E. A., Aguayo A., Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Disease Markers 2009 26 1 35 39 2-s2.0-61349193737 10.3233/DMA-2009-0602
11. Sharief M. K., Hentges R., Association between tumor necrosis factor- α and disease progression in patients with multiple sclerosis. The New England Journal of Medicine 1991 325 7 467 472 2-s2.0-0025773147
12. Probert L., Eugster H., Akassoglu K., Bauer J., Frei K., Lassmann H., Fontana A., TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 2000 123 10 2005 2019 2-s2.0-0033775139
13. Christophi G. P., Christophi J. A., Gruber R. C., Mihai C., Mejico L. J., Massa P. T., Jubelt B., Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN- β 1a treated multiple sclerosis patients. Journal of the Neurological Sciences 2011 307 1-2 41 45 2-s2.0-79959847463 10.1016/j.jns.2011.05.024
14. Swank R. L., Treatment of multiple sclerosis with low-fat diet; results of five and one-half years' experience. American Medical Association Archives of Neurology and Psychiatry 1955 73 6 631 644 2-s2.0-0347876115
15. Swank R. L., Treatment of multiple sclerosis with low-fat diet: result of seven years' experience. Annals of internal medicine 1956 45 5 812 824 2-s2.0-0347245495
16. Swank R. L., Multiple sclerosis: twenty years on low fat diet. Archives of Neurology 1970 23 5 460 474 2-s2.0-0014882936
17. Swank R. L., Goodwin J., Review of MS patient survival on a Swank low saturated fat diet. Nutrition 2003 19 2 161 162 2-s2.0-0037319260 10.1016/S0899-9007(02)00851-1
18. Kurtzke J. F., Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 11 1444 1452 2-s2.0-0021035886
19. Polman C. H., Reingold S. C., Edan G., Filippi M., Hartung H., Kappos L., Lublin F. D., Metz L. M., McFarland H. F., O'Connor P. W., Sandberg-Wollheim M., Thompson A. J., Weinshenker B. G., Wolinsky J. S., Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Annals of Neurology 2005 58 6 840 846 2-s2.0-28544436950 10.1002/ana.20703
20. Edwards P., Questionnaires in clinical trials: guidelines for optimal design and administration. Trials 2010 11 article 2 2-s2.0-76949083246 10.1186/1745-6215-11-2
21. Esterbauer H., Schaur R. J., Zollner H., Chemistry and Biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biology and Medicine 1991 11 1 81 128 2-s2.0-0025814980 10.1016/0891-5849(91)90192-6
22. Salvati S., Natali F., Attorri L., Di Benedetto R., Leonardi F., Di Biase A., Ferri F., Fortuna S., Lorenzini P., Sanchez M., Ricceri L., Vitelli L., Eicosapentaenoic acid stimulates the expression of myelin proteins in rat brain. Journal of Neuroscience Research 2008 86 4 776 784 2-s2.0-40549119867 10.1002/jnr.21537
23. Harris M. A., Hansen R. A., Vidsudhiphan P., Koslo J. L., Thomas J. B., Watkins B. A., Allen K. G. D., Effects of conjugated linoleic acids and docosahexaenoic acid on rat liver and reproductive tissue fatty acids, prostaglandins and matrix metalloproteinase production. Prostaglandins Leukotrienes and Essential Fatty Acids 2001 65 1 23 29 2-s2.0-0034866293 10.1054/plef.2001.0283
24. Harbige L. S., Yeatman N., Amor S., Crawford M. A., Prevention of experimental autoimmune encephalomyelitis in Lewis rats by a novel fungal source of γ -linolenic acid. British Journal of Nutrition 1995 74 5 701 715 2-s2.0-0028809432 10.1079/BJN19950173
25. Harbige L. S., Sharief M. K., Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. British Journal of Nutrition 2007 98 supplement 1 S46 S53 2-s2.0-35148887588 10.1017/S0007114507833010
26. Caughey G. E., Mantzioris E., Gibson R. A., Cleland L. G., James M. J., The effect on human tumor necrosis factor α and interleukin 1 β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. American Journal of Clinical Nutrition 1996 63 1 116 122 2-s2.0-0030038986
27. Bertolotto A., Malucchi S., Capobianco M., Manzardo E., Guastamacchia G., Milano E., Audano L., Mutani R., Quantitative PCR reveals increased levels of tumor necrosis factor- α mRNA in peripheral blood mononuclear cells of multiple sclerosis patients during relapses. Journal of Interferon and Cytokine Research 1999 19 6 575 581 2-s2.0-0032779299 10.1089/107999099313703
28. Scales W. E., Chensue S. W., Otterness I., Kunkel S. L., Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis factor but not interleukin-1 α or β -mRNA and cell-associated bioactivity. Journal of Leukocyte Biology 1989 45 5 416 421 2-s2.0-0024405219
29. Kunkel S. L., Chensue S. W., Arachidonic acid metabolites regulate interleukin-1 production. Biochemical and Biophysical Research Communications 1985 128 2 892 897 2-s2.0-0021826293
30. Endres S., Ghorbani R., Kelley V. E., Georgilis K., Lonnemann G., Van Der Meer J. W. M., Cannon J. G., Rogers T. S., Klempner M. S., Weber P. C., Schaefer E. J., Wolff S. M., Dinarello C. A., The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. The New England Journal of Medicine 1989 320 5 265 271 2-s2.0-0024489402
31. DeLuca P., Rossetti R. G., Alavian C., Karim P., Zurier R. B., Effects of gammalinolenic acid on interleukin-1 beta and tumor necrosis factor-alpha secretion by stimulated human peripheral blood monocytes: studies in vitro and in vivo. Journal of Investigative Medicine 1999 47 5 246 250 2-s2.0-0033124298
32. Ferrante A., Goh D., Harvey D. P., Robinson B. S., Hii C. S. T., Bates E. J., Hardy S. J., Johnson D. W., Poulos A., Neutrophil migration inhibitory properties of polyunsaturated fatty acids. The role of fatty acid structure, metabolism, and possible second messenger systems. Journal of Clinical Investigation 1994 93 3 1063 1070 2-s2.0-0028278545
33. Serhan C. N., Gotlinger K., Hong S., Arita M., Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins and Other Lipid Mediators 2004 73 3-4 155 172 2-s2.0-2942545915 10.1016/j.prostaglandins.2004.03.005
34. Bordoni A., Di Nunzio M., Danesi F., Biagi P. L., Polyunsaturated fatty acids: from diet to binding to ppars and other nuclear receptors. Genes & Nutrition 2006 1 95 106
35. Feinstein D. L., Galea E., Gavrilyuk V., Brosnan C. F., Whitacre C. C., Dumitrescu-Ozimek L., Landreth G. E., Pershadsingh H. A., Weinberg G., Heneka M. T., Peroxisome proliferator-activated receptor- γ agonists prevent experimental autoimmune encephalomyelitis. Annals of Neurology 2002 51 6 694 702 2-s2.0-0036260784 10.1002/ana.10206
36. Shinto L., Marracci G., Bumgarner L., Yadav V., The effects of omega-3 Fatty acids on matrix metalloproteinase-9 production and cell migration in human immune cells: implications for multiple sclerosis. Autoimmune Diseases 2011 2011 6 134592 10.4061/2011/134592
37. Van Horssen J., Witte M. E., Schreibelt G., de Vries H. E., Radical changes in multiple sclerosis pathogenesis. Biochimica et Biophysica Acta 2011 1812 2 141 150 2-s2.0-78650170203 10.1016/j.bbadis.2010.06.011
38. Lindquist S., Hassinger S., Lindquist J. A., Sailer M., The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Multiple Sclerosis 2011 17 7 851 866 2-s2.0-79959499097 10.1177/1352458511399797
39. Bagasra O., Michaels F. H., Zheng Y. M., Bobroski L. E., Spitsin S. V., Fu Z. F., Tawadros R., Koprowski H., Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 1995 92 26 12041 12045 2-s2.0-0029592005 10.1073/pnas.92.26.12041
40. Johnson A. W., Land J. M., Thompson E. J., Bolanos J. P., Clark J. E., Heales J. R., Evidence for increased nitric oxide production in multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry 1995 58 1 107 2-s2.0-0028949360
41. -) levels in cerebrospinal fluid of patients with multiple sclerosis. Journal of the Neurological Sciences 1997 153 1 32 34 2-s2.0-0031443005 10.1016/S0022-510X(97)00183-4
42. Giovannoni G., Heales S. J. R., Silver N. C., O'Riordan J., Miller R. F., Land J. M., Clark J. B., Thompson E. J., Raised serum nitrate and nitrite levels in patients with multiple sclerosis. Journal of the Neurological Sciences 1997 145 1 77 81 2-s2.0-0030893269 10.1016/S0022-510X(96)00246-8
43. Mirshafiey A., Mohsenzadegan M., Antioxidant therapy in multiple sclerosis. Immunopharmacology and Immunotoxicology 2009 31 1 13 29 2-s2.0-60749116052 10.1080/08923970802331943
44. Cendrowski W., Multiple sclerosis and MaxEPA. British Journal of Clinical Practice 1986 40 9 365 367 2-s2.0-0022500266
45. Nordvik I., Myhr K. M., Nyland H., Bjerve K. S., Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurologica Scandinavica 2000 102 3 143 149 2-s2.0-0033840807 10.1034/j.1600-0404.2000. 102003143.x